Confident companies foresee biotechnology expansion in Europe

Commercialization Strategies of Biotechnology Companies

In the biotechnology industry today, there are many business models for project commercialization. These models range from independent vertical integration to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We ...

Financing Development Stage Biotechnology Companies: RMs vs

We examine reverse mergers (RMs) in the biotechnology industry and find that, when compared to initial public offerings (IPOs), RMs are smaller, have significantly lower market valuations relative to size, and generally invest less. We also find that RMs exhibit positive abnormal returns on the announcement date and throughout the first year after the RM event. In looking at liquidity measures,...

Ojects under Foresee Uncertainty

Uncertainty appears as a significant barrier to projects attaining their intended performance goals; thereby contri uting to project failure. Literature on project management under uncertainty has recommended a contingency however based on the premise that the level of uncertainty is static over project duration. We relaxed the assumption by considering variation in the level of uncertainty wit...

A new dawn for marine biotechnology in Europe. Preface.

On 20 June 2010, scientists from across Europe specialising in the field of marine biotechnology gathered at Acquafredda, in the province of Maratea in southern Italy, to attend the European Science Foundation-COST Conference, “Marine Biotechnology: Future Challenges” (Fig. 1). With a programme designed and implemented under the coordination of the Marine Board-ESF, the conference was intention...

Governing conflicts over sustainability: agricultural biotechnology in Europe